Valeant Pharmaceuticals

Activities: Manufacturing Research & Development Pharmaceutical

Trending Articles

  1. Olon strengthens market position with acquisitions ahead of CPHI Milan Two new acquisitions expand Olon’s service offerings and production capacity
  2. Improving the sustainability of pharmaceutical freeze drying with ECO Mode Freeze dryers are typically associated with high levels of energy consumption; to counteract this issue, GEA Pharma & Healthcare has introduced the LYOVAC ECO Mode, which...
  3. Microbial identification of drug contamination: MALDI-TOF MS as an efficient alternative This article describes the growing need for fast and accurate microbial detection in the pharmaceutical manufacturing supply chain
  4. Almac Group announces £11m investment to expand global analytical services The Almac Group has announced an £11m investment and the creation of more than 100 new jobs to expand its global analytical services capabilities
  5. Neopac unveils new Polyfoil mono-material barrier mini tubes Small-size tubes enhance protection and versatility for pharmaceutical and oral care applications

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

Related Content

Finance

Sobi enters into new distribution agreement with Valeant for Ammonul

The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
You need to be a subscriber to read this article.
Click here to find out more.
Media

A precision medicine approach to developing cancer vaccines

Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Design & Build

Valeant Canada expands with $27.5m investment

The company will expand manufacturing and exporting capacity in Steinbach, Manitoba and Laval, Quebec

Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive

He brings more than 30 years of leadership and operations experience in healthcare to the firm

Valeant Pharmaceuticals makes management change

In its US Dermatology and Gastrointestinal businesses

J. Michael Pearson returns as CEO of Valeant following illness

Robert A. Ingram appointed Chairman of the Board as the roles of Chairman and CEO are separated
Regulatory

Opinion: Politics, passion and patient power

Did political correctness play a greater role than therapeutic efficacy in the FDA's decision to approve the 'pink Viagra'?
Subscribe now